Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Tislelizumab in Advanced Urothelial Carcinoma
NCT04562311Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in urothelial carcinoma (UC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 2 years. Started Jan 2021; status: completed.
02
Drugs
tucidinostat
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04562311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562311.